NCT00004095View on ClinicalTrials.gov

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 1999

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Bladder CancerBreast CancerColorectal CancerKidney CancerLung CancerPancreatic Cancer
Interventions
DRUG

gemcitabine hydrochloride

DRUG

irinotecan hydrochloride

Trial Locations (1)

60611

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00004095 - Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter